These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 3691644)

  • 21. In vivo metabolism of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in the rat: identification of urinary metabolites.
    Kanamori T; Inoue H; Iwata Y; Ohmae Y; Kishi T
    J Anal Toxicol; 2002 Mar; 26(2):61-6. PubMed ID: 11916016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differences in the stimulus properties of 3,4-methylenedioxyamphetamine and 3,4- methylenedioxymethamphetamine in animals trained to discriminate hallucinogens from saline.
    Callahan PM; Appel JB
    J Pharmacol Exp Ther; 1988 Sep; 246(3):866-70. PubMed ID: 2901488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurological aspects of hallucinogenic drugs.
    Logan WJ
    Adv Neurol; 1975; 13():47-78. PubMed ID: 814800
    [No Abstract]   [Full Text] [Related]  

  • 24. Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats.
    Fantegrossi WE; Harrington AW; Eckler JR; Arshad S; Rabin RA; Winter JC; Coop A; Rice KC; Woods JH
    Psychopharmacology (Berl); 2005 Sep; 181(3):496-503. PubMed ID: 15983786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of d-lysergic acid diethylamide, d-2-bromolysergic acid diethylamide, dl-2,5-dimethoxy-4-methylamphetamine and d-amphetamine on classical conditioning of the rabbit nictitating membrane response.
    Harvey JA; Gormezano I; Cool VA
    J Pharmacol Exp Ther; 1982 May; 221(2):289-94. PubMed ID: 6122729
    [No Abstract]   [Full Text] [Related]  

  • 26. Characterization of specific binding sites labeled by [3H]LSD in coronal sections of paraformaldehyde-fixed rat brain.
    Beck SG; Azmitia EC
    Brain Res; 1985 Oct; 345(2):369-73. PubMed ID: 4041897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of hallucinogens on spontaneous and sensory-evoked locus coeruleus unit activity in the rat: reversal by selective 5-HT2 antagonists.
    Rasmussen K; Aghajanian GK
    Brain Res; 1986 Oct; 385(2):395-400. PubMed ID: 3096493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants.
    Holze F; Liechti ME; Hutten NRPW; Mason NL; Dolder PC; Theunissen EL; Duthaler U; Feilding A; Ramaekers JG; Kuypers KPC
    Clin Pharmacol Ther; 2021 Mar; 109(3):658-666. PubMed ID: 32975835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dissociations between the effects of hallucinogenic drugs on behavior and raphe unit activity in freely moving cats.
    Trulson ME; Heym J; Jacobs BL
    Brain Res; 1981 Jun; 215(1-2):275-93. PubMed ID: 6114779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification and quantitation of 4-bromo-2,5-dimethoxyamphetamine in seized blotters.
    Burrai L; Nieddu M; Palomba M; Pirisi MA
    Leg Med (Tokyo); 2015 Jan; 17(1):56-9. PubMed ID: 25248801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of lysergic acid diethylamide and mescaline-derived hallucinogens on sensory-integrative function: tactile startle.
    Geyer MA; Petersen LR; Rose GJ; Horwitt DD; Light RK; Adams LM; Zook JA; Hawkins RL; Mandell AJ
    J Pharmacol Exp Ther; 1978 Dec; 207(3):837-47. PubMed ID: 731434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bromo-DMA: the Australasian hallucinogen?
    Buhrich N; Morris G; Cook G
    Aust N Z J Psychiatry; 1983 Sep; 17(3):275-9. PubMed ID: 6580896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Studies on the identification of psychotropic substances. VI. Preparation and various analytical data of reference standards of some hallucinogens, 2,5-dimethoxy-4-methylamphetamine (STP), 2,5-dimethoxy-4-bromoamphetamine (DOB) and 2,5-dimethoxy-4-ethylamphetamine (DOET)].
    Shimamine M; Takahashi K; Nakahara Y
    Eisei Shikenjo Hokoku; 1989; (107):113-9. PubMed ID: 2636911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [3H]DOB: a specific agonist radioligand for 5-HT2 serotonin receptors.
    Titeler M; Herrick K; Lyon RA; McKenney JD; Glennon RA
    Eur J Pharmacol; 1985 Oct; 117(1):145-6. PubMed ID: 4085543
    [No Abstract]   [Full Text] [Related]  

  • 35. Lysergic acid diethylamide (LSD) and tryptamine analogs as potential psychotomimetics.
    Liska KJ; Jain VO; Purich ED
    J Med Chem; 1968 Sep; 11(5):1105-6. PubMed ID: 5697093
    [No Abstract]   [Full Text] [Related]  

  • 36. Receptor pharmacology of MDMA and related hallucinogens.
    Teitler M; Leonhardt S; Appel NM; De Souza EB; Glennon RA
    Ann N Y Acad Sci; 1990; 600():626-38; discussion 638-9. PubMed ID: 1979215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex.
    Marek GJ; Aghajanian GK
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1373-82. PubMed ID: 8819525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical pharmacology of lysergic acid diethylamide: case reports and review of the treatment of intoxication.
    Blaho K; Merigian K; Winbery S; Geraci SA; Smartt C
    Am J Ther; 1997; 4(5-6):211-21. PubMed ID: 10423613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential antagonism by metergoline of the behavioral effects of indolealkylamine and phenethylamine hallucinogens in the rat.
    Commissaris RL; Lyness WH; Moore KE; Rech RH
    J Pharmacol Exp Ther; 1981 Oct; 219(1):170-4. PubMed ID: 6793709
    [No Abstract]   [Full Text] [Related]  

  • 40. Distribution profile of 2,5-dimethoxy-4-bromoamphetamine (DOB) in rats after oral and subcutaneous doses.
    Beránková K; Szkutová M; Balíková M
    Forensic Sci Int; 2007 Aug; 170(2-3):94-9. PubMed ID: 17629428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.